Form Type: 4

SEC EDGAR Link
Acccession Number:0001209191-19-030040
Date:2019-05-13
Issuer: AUDENTES THERAPEUTICS, INC. (BOLD)
Original Submission Date:

Reporting Person:

PRASAD SUYASH
C/O AUDENTES THERAPEUTICS, INC.
600 CALIFORNIA STREET, 17TH FLOOR SAN FRANCISCO, CA 94108

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-05-13 M 10,000 a $0.79 28,236 direct
COMMON STOCK 2019-05-13 S 9,946 d $36.98 18,290 direct
COMMON STOCK 2019-05-13 S 54 d $37.72 18,236 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 0.79 2019-05-13 deemed execution date M 10,000 (d) 2024-02-18 common stock 10,000 $0.79 30,870 direct
Footnotes
IDfootnote
f1 this transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
f2 represents the weighted average sale price. the lowest price at which shares were sold was $36.61 and the highest price at which shares were sold was $37.46. the reporting person undertakes to provide upon request to the staff of the securities exchange commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in this footnote.
f3 the option vested as to 25% of the total shares on february 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on february 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events.

Elevate your investments